HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL.

Abstract
The feasibility and efficacy of cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL (intermediate DLBCL/BL) have never been reported. The effects of adding rituximab to CODOX-M/IVAC have not been published either. Fifteen consecutive patients with a median age of 39 years were treated with modified CODOX-M/IVAC regimen (particularly, reducing the dose of methotrexate to 3 g/m(2)) with or without rituximab at our institution. Although all patients developed grade 4 neutropenia and grade 3/4 thrombocytopenia/anemia, 93% had febrile neutropenia, 60% showed transaminase elevation, and 40% had mucositis/stomatitis (all grade 3), there were no treatment-related deaths. Two of nine patients treated with rituximab developed biphasic late-onset neutropenia. Thirteen patients (87%) showed complete responses. The remaining two patients had refractory disease; one had presented with peritoneal dissemination and complex chromosomal abnormalities, while the other had double IGH-MYC and IGH-BCL2 translocations. The estimated 5-year overall and progression-free survival were 87% each, with a median follow-up of 74 months. In conclusion, our modified CODOX-M/IVAC regimen is well tolerated and highly effective in Japanese adult patients with BL and intermediate DLBCL/BL, warranting a larger study for confirmation.
AuthorsDai Maruyama, Takashi Watanabe, Akiko Miyagi Maeshima, Junko Nomoto, Hirokazu Taniguchi, Teruhisa Azuma, Masakazu Mori, Wataru Munakata, Sung-Won Kim, Yukio Kobayashi, Yoshihiro Matsuno, Kensei Tobinai
JournalInternational journal of hematology (Int J Hematol) Vol. 92 Issue 5 Pg. 732-43 (Dec 2010) ISSN: 1865-3774 [Electronic] Japan
PMID21120644 (Publication Type: Journal Article)
Chemical References
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents
  • Cytarabine
  • Rituximab
  • Vincristine
  • Etoposide
  • Doxorubicin
  • Cyclophosphamide
  • Ifosfamide
  • Methotrexate
Topics
  • Adult
  • Antibodies, Monoclonal, Murine-Derived (therapeutic use)
  • Antineoplastic Agents (administration & dosage)
  • Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
  • Burkitt Lymphoma (drug therapy, pathology)
  • Cyclophosphamide (administration & dosage)
  • Cytarabine (administration & dosage)
  • Disease-Free Survival
  • Doxorubicin (administration & dosage)
  • Etoposide (administration & dosage)
  • Female
  • Humans
  • Ifosfamide (administration & dosage)
  • Lymphoma, B-Cell (drug therapy, pathology)
  • Male
  • Methotrexate (administration & dosage)
  • Middle Aged
  • Rituximab
  • Treatment Outcome
  • Vincristine (administration & dosage)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: